INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2018

Amla tablets significantly reduced the frequency and severity of heartburn and regurgitation compared to placebo in patients with non-erosive reflux disease.

A double-blind, randomized, placebo-controlled trial evaluated the efficacy of Amla (Phyllanthus emblica L.) tablets in 68 patients with non-erosive reflux disease. Participants took two 500 mg Amla tablets or placebo twice daily after meals for 4 weeks. Heartburn and regurgitation frequencies significantly dropped in both groups (P < 0.001), but repeated measures logistic regression demonstrated a significantly greater reduction in the frequency and severity of both heartburn and regurgitation in the Amla group compared to placebo (P < 0.001).

Study type
Double-blind, randomized, placebo-controlled trial
Who was studied
68 patients with classic GERD symptoms for at least three months
What was measured
Frequency and severity of heartburn and regurgitation

THE PAPER

Efficacy and safety of Amla (Phyllanthus emblica L.) in non-erosive reflux disease: a double-blind, randomized, placebo-controlled clinical trial.

Karkon Varnosfaderani S, Hashem-Dabaghian F, Amin G, Bozorgi M, Heydarirad G, Nazem E, Nasiri Toosi M, Mosavat SH. J Integr Med, 2018.

PubMed 29526236 ↗DOI 10.1016/j.joim.2018.02.008 ↗

Gut & microbiome

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.